HORIBA launches Veloci™ A-TEEM™ BioPharma Analyzer to accelerate biopharmaceutical analysis

HORIBA has launched the Veloci™ A-TEEM™ BioPharma Analyzer, a biopharma analyzer with A-TEEM (simultaneous Absorbance, Transmittance, and Fluorescence Excitation-Emission-Matrix (EEM)) Technology, providing advanced molecular fingerprinting for life science applications in the biopharma and pharma industries. The analyzer is designed for researchers, process analytical technology (PAT) specialists, and QA/QC teams who need faster, more cost-effective, and environmentally friendly biopharmaceutical analysis.

Advanced A-TEEM spectroscopy for biopharma and pharma

The Veloci BioPharma Analyzer is a unique A-TEEM spectroscopy solution that combines the selectivity of chromatography with the advantages of optical spectroscopy. This technology delivers a fast, cost-effective, and user-friendly approach to component analysis and removes the need for traditional column-based separations.

By acquiring simultaneous absorbance, transmittance, and fluorescence EEM data, the analyzer provides advanced molecular fingerprinting capabilities for a wide range of life science and pharmaceutical applications.

Label-free intrinsic fluorescence for high-precision applications

The Veloci BioPharma Analyzer utilizes label-free intrinsic fluorescence analysis, providing high precision and efficiency across multiple biopharmaceutical workflows. Key application areas include:

• Monoclonal antibody discrimination
• Cell media monitoring
• Vaccine characterization
• Protein stability analysis
• Adeno-associated virus (AAV) quantification

This label-free approach enables analysis of samples in their natural state, supporting both research and manufacturing environments.

Faster, greener alternative to traditional chromatography

The analyzer combines the selectivity of chromatography with the speed and simplicity of spectroscopy, offering superior sensitivity compared to traditional methods such as high performance liquid chromatography (HPLC), mass spectrometry (MS), and Raman spectroscopy.

The Veloci A-TEEM BioPharma Analyzer requires no sample preparation or solvent use. It accelerates workflows with analysis times as short as three minutes per sample for the hundreds of EEM spectra acquired and processed. This is significantly faster than traditional methods such as ultra performance liquid chromatography (UPLC), which can take around 30 minutes per sample, reducing both time and environmental impact.

Key capabilities of the Veloci A-TEEM BioPharma Analyzer

The Veloci A-TEEM BioPharma Analyzer supports a broad range of biopharmaceutical and life science applications, including:

• When analyzing antibody drug conjugates, distinguishing between the monoclonal antibody (mAb) portion of the drug, the payload, and the linker, even with over 90% sequence homology, delivering rapid and accurate intrinsic fluorescence analysis in their natural state.
• Measuring capsid empty/full ratios and differentiating AAV subtypes in a label-free manner, bypassing the need for analytical centrifuges.
• Monitoring cell culture media quality for bioreactors to support consistent bioprocessing.
• Providing vaccine characterization by identifying formulations, detecting aggregation, and monitoring batch-to-batch variations.
• Offering protein stability assessment by detecting early signs of aggregation, helping safeguard against reduced potency and increased side effects.
• Discriminating between exosome subtypes, enabling advanced studies on extracellular signaling and therapeutic applications.

Streamlined workflows, PAT integration, and compliance

Cary Davies, global product line manager for fluorescence products at HORIBA, said, “The Veloci Biopharma Analyzer is a significant advancement of our core A-TEEM spectroscopy product line by offering our industrial partners easy workflows and multivariate analysis, a new open platform communications (OPC) unified architecture (UA) process analytical technology (PAT) interface and full compliance solutions.”

This integration with OPC UA and PAT frameworks supports implementation in manufacturing control strategies and regulated environments, aligning with modern biopharmaceutical production requirements.

A-TEEM technology for QA/QC and manufacturing control

Andrew Whitley, Vice President and Field Officer for the HORIBA Life Science Business Field, said, “The pharmaceutical industry is increasingly using fluorescence spectroscopy, and more specifically, ATEEM for QA/QC and as a process analytical technology (PAT) for manufacturing control. A-TEEM provides similar information to mass spectrometry and chromatography, but faster and easier, typically no consumables, while like any optical technique is easily implemented.” Andrew continued, “Veloci’s ATEEM Technology offers the speed, cost-effectiveness and solutions required across research, PAT and QA/QC.”

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>